Exclusive Summary

• Tirofiban Hydrochloride Injection, as a fast-acting antiplatelet drug, has clear indications and large market demand, especially in periprocedural PCI and acute coronary syndrome treatment.
• The original patent has expired, leading to a competitive yet large global generic drug market, with significant room for penetration in emerging economies.
• The product has passed China's consistency evaluation and features in-house API production, ensuring high quality, controllable costs, and stable supply, which will be a competitive advantage globally.
• Tirofiban Hydrochloride Injection is listed in the WHO Model List of Essential Medicines and recommended in multiple international guidelines as a first-line or second-line treatment.
• Significant cost advantage over the originator product provides strong price competitiveness, facilitating market share expansion.

Asset Materials

Contact Us for Full Materials